Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Surgeon General Links Obesity to Cancer

February 1, 2002
Publication
Article
OncologyONCOLOGY Vol 16 No 2
Volume 16
Issue 2

A recent report on obesity released by US Surgeon General Dr. David Satcher said that about 300,000 people in the United States die each year from diseases related directly to being overweight, including heart disease and cancer.

A recent report on obesity released by US SurgeonGeneral Dr. David Satcher said that about 300,000 people in the United Statesdie each year from diseases related directly to being overweight, includingheart disease and cancer. 

The report, entitled "The Surgeon General’sCall to Action to Prevent and Decrease Overweight and Obesity," outlinedstrategies that communities can use in helping to address the problem. Thoseoptions include requiring physical education at all school grades, providingmore healthy food options on school campuses, and providing safe and accessiblerecreational facilities for residents of all ages. The report links beingoverweight or obese with an increased risk for some types of cancer includingendometrial, colon, gall bladder, prostate, kidney, and postmenopausal breastcancer. Women gaining more than 20 lb from age 18 to midlife double their riskof postmenopausal breast cancer, compared to women whose weight remains stable.

Articles in this issue

Surgeon General Links Obesity to Cancer
Medicare Delays New Outpatient Payment System
New Report on Nation’s Progress Against Cancer Released
Atlas of Breast Cancer, Second Edition
Subcutaneous Amifostine May Be as Effective as Intravenous Administration
Newly Designated NCI Director Roundly Applauded by Cancer Community

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Related Content

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent with IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 11th 2025
Podcast

In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 11th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 11th 2025
Podcast

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Ariana Pelosci
September 11th 2025
Article

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 11th 2025
Article
Related Content

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent with IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 11th 2025
Podcast

In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 11th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 11th 2025
Podcast

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Ariana Pelosci
September 11th 2025
Article

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 11th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.